Drug Repurposing Market Report 2026

Drug Repurposing Market Overview

• Drug Repurposing market size has reached to $37.38 billion in 2025 • Expected to grow to $58.33 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Surge In Age-Related Brain Disorders Fueling The Growth Of The Market Due To Increased Life Expectancy • Market Trend: AI-Powered Drug-Protein Interaction Modeling Revolutionizes Repurposing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Drug Repurposing Market?

Drug repurposing is the process of identifying new therapeutic uses for existing or previously failed drugs. It leverages known safety profiles and pharmacology to reduce development time and cost. The purpose is to efficiently bring treatments to market by bypassing early-stage drug discovery steps. The main types of drug repurposing are disease-centric, target-centric, and drug-centric. Disease-centric refers to repurposing drugs by focusing on a specific disease and testing various existing drugs to see if they can treat that disease, regardless of their original target. The multiple drug molecules involved are biologics and small molecules. The various therapeutic areas include oncology, neurology, infectious diseases, cardiovascular diseases, and autoimmune disorders through various routes of administration: oral, intravenous, topical, inhalation, and intramuscular, and cater to several end users such as pharmaceutical companies, research and academic institutes, and contract research organizations.

What Is The Drug Repurposing Market Growth Forecast?

The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $58.33 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to integration of ai and machine learning in drug repurposing, growing investment in biotech and pharma research, expansion of contract research organizations (cros) capabilities, rising demand for affordable therapies, regulatory support for repurposed drug approvals. Major trends in the forecast period include increasing focus on phenotypic and target-based screening, rising adoption of structure-based drug repositioning, growth in off-target activity identification approaches, expansion of drug repurposing for rare and infectious diseases, shortening drug development timelines through existing molecules.

Global Drug Repurposing Market Segmentation

1) By Type: Disease-Centric, Target-Centric, Drug-Centric 2) By Drug Molecules: Biologics, Small Molecule 3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders 4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular 5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations Subsegments: 1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing 2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting 3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

What Is The Driver Of The Drug Repurposing Market?

The growing prevalence of neurodegenerative diseases is expected to propel the growth of the drug repurposing market going forward. Neurodegenerative diseases refer to a group of disorders characterized by the progressive loss of structure or function of neurons, including their death. The rise in neurodegenerative diseases such as alzheimer's dementia is due to increased life expectancy, as aging is the primary risk factor that contributes to the gradual decline of neuronal function over time. Drug repurposing helps neurodegenerative diseases by identifying existing drugs with known safety profiles that can be redirected to target disease pathways, accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, in 2023, about 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is driving the growth of the drug repurposing industry.

Key Players In The Global Drug Repurposing Market

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Global Drug Repurposing Market Trends and Insights

Major companies operating in the drug repurposing market are focusing on developing advanced technologies such as artificial intelligence (AI)-powered drug-protein interaction modeling to accelerate the identification of new therapeutic uses for existing drugs. Artificial intelligence (AI)-powered drug-protein interaction modeling leverages artificial intelligence and machine learning to predict how drugs interact with proteins across the human proteome, using expansive datasets to enhance accuracy and confidence. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, unveiled Cloudscreen 2.0, an advanced AI platform for drug repurposing. It is a next-generation system designed to process datasets over 100 times larger than before, enabling comprehensive analysis of drug-protein interactions. By incorporating mutagenesis data and tools for analyzing disordered proteins, the platform targets diseases such as cancer, obesity, and diabetes. Additionally, graphics processing unit (GPU)-based cloud computing empowers scalable processing, making the platform a critical innovation in accelerating research and development pipelines for drug repurposing across multiple therapeutic areas.

What Are Latest Mergers And Acquisitions In The Drug Repurposing Market?

In July 2025, Predictive Oncology Inc., a US-based artificial intelligence-driven drug discovery and repurposing company, partnered with YA II PN, Ltd., to secure a $10 million share purchase agreement. Through this partnership, Predictive Oncology aims to advance its AI-driven platform to accelerate the identification of new therapeutic uses for existing drugs and streamline oncology drug discovery processes. YA II PN, Ltd. is a US-based investment fund managed by Yorkville Advisors Global, LP, a US-based investment management services providing financing to support initiatives.

Regional Insights

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Drug Repurposing Market?

The drug repurposing market consists of revenues earned by entities by providing services such as computational drug screening, clinical trial design and support, regulatory consulting, bioinformatics analysis, and data mining of existing drug databases. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug repurposing market also includes sales of thalidomide, sildenafil, minoxidil, metformin, and azithromycin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drug Repurposing Market Report 2026?

The drug repurposing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drug repurposing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.